LifeVantage Co. (NASDAQ:LFVN) Short Interest Up 137.5% in February

LifeVantage Co. (NASDAQ:LFVN) was the target of a significant growth in short interest during the month of February. As of February 15th, there was short interest totalling 1,410,000 shares, a growth of 137.5% from the January 31st total of 593,800 shares. Based on an average daily trading volume, of 214,300 shares, the days-to-cover ratio is presently 6.6 days. Currently, 14.0% of the shares of the stock are sold short.

Analysts Set New Price Targets

Several brokerages have weighed in on LFVN. Craig Hallum began coverage on LifeVantage in a report on Tuesday, January 14th. They set a “buy” rating and a $35.00 price objective for the company. Lake Street Capital assumed coverage on LifeVantage in a research note on Thursday, December 19th. They issued a “buy” rating and a $26.00 price target for the company.

LifeVantage Price Performance

Shares of LFVN stock opened at $17.17 on Friday. The stock has a market cap of $215.50 million, a PE ratio of 30.66 and a beta of 0.84. The stock has a 50-day moving average of $20.10 and a 200-day moving average of $14.87. LifeVantage has a one year low of $5.22 and a one year high of $27.38.

LifeVantage (NASDAQ:LFVN) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.08. LifeVantage had a return on equity of 34.29% and a net margin of 3.46%.

LifeVantage Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 17th. Investors of record on Monday, March 3rd will be given a $0.04 dividend. The ex-dividend date is Monday, March 3rd. This represents a $0.16 annualized dividend and a dividend yield of 0.93%. LifeVantage’s dividend payout ratio is presently 28.57%.

Insider Activity at LifeVantage

In other LifeVantage news, Director Raymond B. Greer sold 8,000 shares of the business’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $20.15, for a total transaction of $161,200.00. Following the completion of the sale, the director now directly owns 99,288 shares of the company’s stock, valued at approximately $2,000,653.20. The trade was a 7.46 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 20.65% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On LifeVantage

Institutional investors and hedge funds have recently modified their holdings of the business. Hillsdale Investment Management Inc. boosted its position in LifeVantage by 7.3% during the 4th quarter. Hillsdale Investment Management Inc. now owns 14,720 shares of the company’s stock worth $258,000 after acquiring an additional 1,000 shares during the last quarter. Barclays PLC boosted its position in LifeVantage by 3.6% during the 4th quarter. Barclays PLC now owns 43,472 shares of the company’s stock worth $763,000 after acquiring an additional 1,506 shares during the last quarter. Copeland Capital Management LLC acquired a new position in LifeVantage during the 4th quarter worth approximately $65,000. Northern Trust Corp boosted its position in LifeVantage by 27.6% during the 4th quarter. Northern Trust Corp now owns 44,176 shares of the company’s stock worth $774,000 after acquiring an additional 9,552 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC acquired a new position in LifeVantage during the 4th quarter worth approximately $282,000. 35.32% of the stock is currently owned by institutional investors and hedge funds.

About LifeVantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.